Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject in Hospitalized Patients With HFpEF and Iron Deficiency
NCT05793996Phase 4Recruiting
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose in heart failure with preserved ejection fraction (HFpEF) and iron deficiency anemia (IDA) (3 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoint: Combined Primary Outcome at 12 months. Started Apr 2023; status: recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05793996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05793996.